Ovarian Cancer Vaccine for Patients in Remission

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

August 31, 2013

Study Completion Date

April 30, 2015

Conditions
Epithelial Ovarian Cancer
Interventions
BIOLOGICAL

Cvac

Cvac consists of autologous dendritic cells (DCs) incubated with the antigen, mannosylated fusion protein (M-FP), to target the DCs to the specific mucin 1 antigen.

Trial Locations (18)

3002

Peter MacCallum Cancer Cetnre, East Melbourne

3084

Austin Health Cancer Centre, Heidelberg

4120

Greenslopes Private Hospital, Greenslopes

4215

Gold Coast Hospital, Southport

5000

Royal Adelaide Hospital, Adelaide

10038

New York Downtown Hospital, New York

27710

Duke University Medical Center, Durham

29425

Medical University of South Carolina, Charleston

30342

Northside Hospital, Atlanta

33487

Collaborative Research Group, Boca Raton

44195

Cleveland Clinic Foundation, Cleveland

46202

Indiana University Simon Cancer Center, Indianapolis

92037

Scripps Cancer Center, La Jolla

94115

University of California, San Francisco, San Francisco

94305

Stanford University School of Medicine, Palo Alto

94904

Marin Cancer Care, Inc., Greenbrae

98109

University of Washington Medical Center, Seattle

07962

Morristown Medical Center, Morristown

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Prima BioMed Ltd

INDUSTRY